TIGIT Inhibitors - Competitive Landscape, 2022

TIGIT Inhibitors - Competitive Landscape, 2022

DelveInsight’s, “TIGIT inhibitors - Competitive landscape, 2022,” report provides comprehensive insights about 18+ companies and 20+ drugs in TIGIT inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TIGIT inhibitors: Understanding

TIGIT inhibitors: Overview

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain. It is expressed on activated and memory T cells, NK cells, and Tregs. Binding to either of its two ligands on APCs, CD155 (PVR: poliovirus receptor) and CD112 (PVRL2, nectin-2), prevents their maturation and confers a tolerogenic phenotype. Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. Mechanistally, research has shown that TIGIT-Fc fusion protein could interact with PVR on dendritic cells and increase its IL-10 secretion level/decrease its IL-12 secretion level under LPS stimulation, and also inhibit T cell activation in vivo. TIGIT's inhibition of NK cytotoxicity can be blocked by antibodies against its interaction with PVR and the activity is directed through its ITIM domain.

Report Highlights

In December 2021, Bio-Thera Solutions a commercial-stage pharmaceutical company announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT6005, a monoclonal antibody targeting TIGIT in cancer patient volunteers.

In June 2021, GlaxoSmithKline and iTeos Therapeutics announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer. TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial.

Company Profiles & their Late-stage Drug Profiles

1. Company Overview: BeiGene

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, company is committed to expediting the development of our diverse pipeline of novel therapeutics through collaborations or our own internal capabilities, with the aspirational goal of radically improving access to medicines for two billion more people by 2030.

Product Description: Ociperlimab

Ociperlimab (BGB-A1217) is an investigational humanized monoclonal antibody designed to bind to TIGIT with high specificity and affinity. Ociperlimab is one of the most advanced anti-TIGIT antibodies in development with an intact IgG Fc binding region for optimal antibody-mediated anti-tumor activity. Ociperlimab binds to TIGIT and blocks its interactions with the poliovirus receptor (CD155) and poliovirus receptor-related 2 (CD112) ligands on tumor cells, resulting in activation of T cell mediated antitumor immune responses.

2. Company Overview: Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases.

Product Description: BAT6005

BAT6005 is a monoclonal antibody targeting TIGIT in cancer patient volunteers. BAT6005 was discovered using Bio-Thera’s proprietary IDEAL (Intelligent Design and Engineered Antibody Libraries) platform, and it has normal IgG1 ADCC function.

Further product details are provided in the report……..

Future of Competitive Landscape of TIGIT inhibitors is estimated to be very strong. Key emerging drugs include BeiGene, Ociperlimab and many other.

TIGIT inhibitors Analytical Perspective by DelveInsight

In-depth TIGIT inhibitors analysis: Assessment of Products

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

TIGIT inhibitors clinical assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type.

TIGIT inhibitors Report Assessment

Company Analysis

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing TIGIT inhibitors drugs?

How many TIGIT inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIGIT inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIGIT inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TIGIT inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Merck Sharp & Dohme

Bristol-Myers Squibb

BeiGene

Arcus Biosciences

iTeos Therapeutics

Mereo BioPharma

Phio Pharmaceuticals

Bio-Thera Solutions

Compugen

Key Products

Vibostolimab

BMS 986442

Ociperlimab

Domvanalimab

EOS 448

Etigilimab

PH 804-TME

PH 804-ACT

BAT6005

Vibostolimab

M 6223

COM 902

BMS 986442